skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

​Drive commercial success

drive commerical success pharma intelligence

As a pharmaceutical company, you need to continually evaluate your disease strategy to discern gaps in your portfolio and decide whether to build or buy. Internal candidates need to be assessed against competitors’ pipelines, and assets suitable for expanding your portfolio identified. To do all this, the right data and analysis is essential.

How we can help

Our portfolio strategy solutions give you timely and accurate intelligence you can act on, including:

  • A wealth of expert insights gathered by our global team of more than 65 journalists and over 300 specialist analysts
  • The most up-to-date, comprehensive coverage of drugs, companies, epidemiology, diseases, strategy, and pricing and reimbursement trends
  • Sales forecasts for pipeline candidates and patient-based sales forecasts from surveys of more than 200 physicians per indication
  • Country-specific treatment algorithms and reimbursement scenarios
  • Comprehensive and timely market research reports to help you understand macro trends and synthesize key insights so the ‘big picture’ always informs your commercial decisions
  •  Our Ask-the-Analyst™ service that puts you in direct contact with our global analyst team

Relevant products

video-thumb-sample

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

  • Prioritize market opportunities
  • Identify unmet needs
  • Make informed decisions
video-thumb-sample

Pharmapremia: Benchmark better and optimize your drug development pipeline

Using a peer-reviewed methodology that provides robust, unbiased drug phase success rates and timeline metrics by treatment indication, Pharmapremia enables you to make strong, informed decisions about your drug development pipeline.

Key benefits:

  • Manage portfolio risks
  • Analyze success factors
  • Create meaningful benchmarks
video-thumb-sample

In Vivo: strategic insights for life sciences decision-makers

In Vivo offers comprehensive coverage of the global medical industry’s competitive landscape.

Key benefits:

  • Cutting edge thought leadership
  • Expert analysis
  • Hear from news makers

Pharma Intelligence latest insights

  • In Vivo

    True Innovation In Women's Health Hindered Because Conditions Are Not Fatal

    By Lucie Ellis 17 Aug 2018

    Drug developers and financiers discuss the biggest challenges delaying novel R&D in diseases effecting only women and how poor awareness of the debilitating symptoms that come with some conditions has led to a lack of emphasis on innovative research.

    Topic Drug approval Drug review

  • In Vivo

    Cancer's New Patient Demographic; Will Survivorship Change The Face Of Cancer Care?

    By William Looney 13 Aug 2018

    The 16 million survivors of cancer in the US today form a restless constituency with its own disparate set of interests – and by sheer weight of numbers is beginning to direct changes to medical practice that pose both risks and opportunity for biopharma.

    Topic Cancer

  • In Vivo

    NASH: Flying The Plane While Building It

    By Amama Sadiq, Iliyana P. Atanasova, Katherine J. Franklin 03 Aug 2018

    Drug development for nonalcoholic steatohepatitis (NASH), a form of liver disease, is a game of incomplete information: pipeline evolution is occurring in parallel with continued efforts to better understand and manage the disease. To date, no therapy for patients with NASH has been approved and consequences of the condition can be severe, including cirrhosis and hepatocellular carcinoma.

    Topic Clinical trials

  • In Vivo

    Ortho Demand Pull: DePuy Synthes Shaping Its Digital And Robotic Surgery Strategy Around Patient Needs

    By Ashley Yeo 26 Jul 2018

    Johnson & Johnson's DePuy Synthes orthopedic business has taken a measured view of digital and robotic capabilities, rather than acquiring assets that perhaps do not fully meet its strategic needs. For the business's global R&D head Euan Thomson, any new technology must augment the group's abilities to drive meaningful outcomes.

    Topic Digital Health

  • In Vivo

    Cancer Vaccines: Is There A Future Beyond Trial And Error?

    By William Looney 12 Jul 2018

    Strong foundational research in immunology and some promising early phase trial results have so far failed to expedite the validation of vaccines to treat cancer. In Vivo examines biopharma’s enduring optimism about the future of cancer vaccinology, including a closer look at one company’s platform to tackle the incurable malignancies that beset the mother of all organs: the human brain.

    Topic Cancer Vaccines

  • In Vivo

    Back To The Future: Novo’s Sørensen Reflects On CEO Years And Tasks Ahead For Industry

    By Lucie Ellis 06 Jul 2018

    Lars Rebien Sørensen scrutinizes the pharmaceutical industry and shares with In Vivo his vision for the future of the Novo Nordisk Foundation. With 16 years as CEO of Novo Nordisk under his belt, as well as many more years in leadership roles at the Danish company, Sørensen reflects on the past and gives his predictions for the future of the innovative drug development sector.

    Topic Drug development landscape Business strategies

  • Datamonitor Healthcare

    Business Development and Licensing Video

    01 Jul 2018

    If you’re a senior business development and licensing professional in pharma or biotech, it’s your job to ensure that your company’s revenue pipeline is full of viable opportunities and accelerate growth for your organisation. Watch this short video  and discover how Informa’s Pharma Intelligence provides the rock-solid intelligence you need to accelerate growth and drive business forward.

    Topic Business strategies

  • Datamonitor Healthcare

    Japan Pharma Outlook Webinar Recording

    By Ian Haydock 01 Jul 2018

    Listen to this insightful presentation of the unique challenges and opportunities faced by Japan Pharma, hosted by the expert analysts from Pharma Intelligence.

    Topic Drug development landscape

  • In Vivo

    Bayer’s US Playbook: The Smart Way To Top-Line Growth

    By William Looney 28 Jun 2018

    The hotly contested US market is central to Bayer’s aspirations to become a global innovation player in pharmaceuticals, especially in key growth segments like oncology. A little more than one year in, Bayer Pharmaceuticals Americas President Dr. Carsten Brunn reflects on his unit’s progress.

    Topic Business strategies Company analysis

  • In Vivo

    Pharma’s New R&D Models: Federating Innovation

    By Melanie Senior 28 Jun 2018

    Experiments are underway to solve pharma’s well-documented R&D productivity crisis. The industry is no longer focused only on buying new drugs via M&A, or on outsourcing discovery. Companies are also building new channels through which to access innovation, setting up different kinds of partnerships, and using new kinds of data. The shift involves re-thinking pharma’s place in healthcare.

    Topic Research Drug development landscape

  • Datamonitor Healthcare

    Trends in Gene Therapy Seminar

    By Patricia Reilly 27 Jun 2018

    The promises of gene therapy are taking a long time to be fulfilled, in part due to challenges in developing gene vectors capable of safe and efficient delivery of therapeutic genes (transgenes) into patients’ cells. Nonetheless, these challenges are being addressed in innovative ways. A variety of first-generation vectors, both viral and non-viral, have been employed in clinical trials with varying degrees of success, and the experience gained is guiding the design of next-generation vectors.

  • Datamonitor Healthcare

    Acute Myeloid Leukemia Market Outlook Seminar

    By Dominique Fontanilla 27 Jun 2018

    There has been little change to standard treatment for AML in recent years; however, 2017 saw a flurry of new targeted drug approvals, sparking significant market growth. Patient age remains the biggest factor in driving treatment decisions for AML. Cases of AML are expected to increase, and prognosis remains poor – especially among older adults. Drug developers are targeting patient segments with high unmet clinical need to gain access to the AML market and the budget impact of AML is expected to grow considerably.

    Topic Cancer

  • In Vivo

    World In Motion The Shape Of The New Health Care Technology Ecosystem In 2022

    By Ashley Yeo 14 Jun 2018

    The health products industry, methods of care delivery and even the public's expectations for improved tools to prevent, monitor and treat disease have transformed dramatically in the past five years. The changes anticipated over a similar period ahead are potentially even more marked, with business continuity impacts for medtech and pharma concerns, according to Deloitte LLP experts who were on the circuit at health care industry events in Germany and the UK this spring.

    Topic Business strategies Digital Health

  • In Vivo

    How The EHR And New Data Streams Are Influencing Clinical Practice

    By Mark Ratner 14 Jun 2018

    A plethora of clinical studies are showing that new types of data, often captured in the EHR, can help improve the correlation between treatments and outcomes and favorably affect patient care as well as enhance drug development.

  • Datamonitor Healthcare

    Datamonitor Healthcare Analyst Podcast: Post-ASCO Podcast 1

    By Jack Allen 08 Jun 2018

    Zach McLellan and Jack Allen are joined by guest analysts Dominique Fontanilla and Hardik Patel. The group discusses key recent events that occurred at the American Society of Clinical Oncology 2018 Annual Meeting.

    Topic Cancer

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: